Fund details
Series |
Currency |
Fund code |
MER * (%) |
|---|---|---|---|
| F | CAD | 35075 | 0.99% |
Portfolio analysis As of Mar 31, 2025
99%
1%
Equity
Fixed Income
Asset mix
Equity Sector Allocation
Financials26.1%
Industrials17.8%
Health Care15.6%
Consumer Staples9.5%
Consumer Discretionary9.0%
Materials8.4%
Information Technology7.1%
Energy3.6%
Utilities3.0%
Top 10 Holdings |
% Assets |
|---|---|
| EssilorLuxottica SA | 4.1% |
| Roche Holding AG | 3.7% |
| Allianz SE | 3.4% |
| AstraZeneca PLC | 3.4% |
| Novo Nordisk A/S - Class B Shares | 3.4% |
| ASML Holding NV | 3.3% |
| London Stock Exchange Group PLC | 3.0% |
| Unilever PLC | 3.0% |
| Air Liquide SA | 2.9% |
| UBS Group AG | 2.8% |
| Total % of Top 10 Holdings | 33.0% |
Geographic allocation
Region
- Europe100.0%
Performance analysis
Growth of $10,000 since inception
Calendar returns
Trailing return
| 1 Mth | 3 Mth | 6 Mth | 1 year | 3 years | 5 years | 10 years | Since Inception | |||
|---|---|---|---|---|---|---|---|---|---|---|
| -0.6 | -0.6 | 3.2 | 7.1 | 10.2 | 10.2 | 6.3 | 4.8 | Fund |
Distribution ($)/unit
| YTD* | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total distributions | 0.52 | 1.12 | 1.00 | 0.46 | 1.62 | 0.41 | 0.48 | 1.09 | 1.20 | 0.59 | 0.28 |
| Interest | --- | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | --- | --- | --- |
| Canadian dividends | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Foreign dividends | --- | 0.56 | 0.59 | 0.43 | 0.34 | 0.30 | 0.51 | 0.55 | 0.39 | 0.34 | 0.32 |
| Foreign taxes paid | --- | -0.07 | -0.06 | -0.04 | -0.03 | -0.03 | -0.04 | -0.06 | -0.04 | -0.03 | -0.04 |
| Capital gains | --- | 0.63 | 0.46 | 0.06 | 1.30 | 0.14 | --- | 0.60 | 0.85 | 0.28 | --- |
| Return of capital | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
* MER (%) is based on actual expenses for the preceding calendar year or most recent half-year period ended June 30 expressed on an annualized basis, depending on availability of date at the time of publication.